Au Revoir Genzyme; Sanofi Stakes Its Claim With $20.1 Billion Upfront And CVRs
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis finally struck a deal to acquire Genzyme for $20.1 billion plus potential future payments, but successfully integrating the company remains the challenge.
You may also be interested in...
BioMarin Negotiates For Aldurazyme With Sanofi-Aventis
The mash-up between Sanofi and Genzyme will have a large effect on one of the biotech's other partners.
BioMarin Negotiates For Aldurazyme With Sanofi-Aventis
The mash-up between Sanofi and Genzyme will have a large effect on one of the biotech's other partners.
In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal
MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors